5:38 PM
 | 
Oct 05, 2012
 |  BC Extra  |  Clinical News

XenoPort up on Phase I data for potential autoimmune therapy

XenoPort Inc. (NASDAQ:XNPT) gained $1.71 (15%) to $12.86 on Friday after reporting Phase I pharmacokinetic and safety data for XP23829, an oral prodrug of monomethyl fumarate (MMF) that...

Read the full 127 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >